TABLE OF CONTENT 1 EXECUTIVE SUMMARY 1.1 MARKET SYNOPSIS 16 1.2 MARKET ATTRACTIVENESS ANALYSIS 17 2 MARKET INTRODUCTION 2.1 DEFINITION 18 2.2 SCOPE OF THE STUDY 18 2.3 RESEARCH OBJECTIVE 18 2.4 MARKET STRUCTURE 18 2.5 ASSUMPTIONS & LIMITATIONS 19 3 RESEARCH METHODOLOGY 3.1 DATA MINING 20 3.2 SECONDARY RESEARCH 21 3.3 PRIMARY RESEARCH 22 3.4 BREAKDOWN OF PRIMARY RESPONDENTS 23 3.5 FORECASTING TECHNIQUES 24 3.6 RESEARCH METHODOLOGY FOR MARKET SIZE ESTIMATION 25 3.6.1 BOTTOM-UP APPROACH 26 3.6.2 TOP-DOWN APPROACH 26 3.7 DATA TRIANGULATION 27 3.8 VALIDATION 27 4 MARKET DYNAMICS 4.1 OVERVIEW 28 4.2 DRIVERS 29 4.2.1 RISING PREFERENCE OF PERSONALIZED MEDICINE 29 4.2.2 INCREASING PRODUCT APPROVAL BY MAJOR PLAYERS 29 4.2.3 INCREASING COLLABORATION AMONG COMPANIES AND DRUG-DIAGNOSTIC CO-DEVELOPMENT 30 4.2.4 INCREASING GLOBAL INCIDENCE OF CANCER 30 4.3 RESTRAINTS 31 4.3.1 LACK OF REIMBURSEMENT IN DEVELOPING REGIONS 31 4.4 OPPORTUNITIES 32 4.4.1 ENTRY OF MARKET PLAYERS INTO EMERGING ECONOMIES 32 5 MARKET FACTOR ANALYSIS 5.1 PORTER’S FIVE FORCES MODEL 33 5.1.1 THREAT OF NEW ENTRANTS 33 5.1.2 BARGAINING POWER OF SUPPLIERS 34 5.1.3 THREAT OF SUBSTITUTES 34 5.1.4 BARGAINING POWER OF BUYERS 34 5.1.5 INTENSITY OF RIVALRY 34 5.2 SUPPLY CHAIN ANALYSIS 35 5.2.1 R&D AND DESIGNING 36 5.2.2 MANUFACTURING 36 5.2.3 DISTRIBUTION 36 5.2.4 MARKETING & SALES 36 5.2.5 POST-SALES MONITORING 36 5.3 IMPACT OF COVID-19 ON THE GLOBAL COMPANION DIAGNOSTICS FOR ONCOLOGY MARKET 36 5.3.1 OVERVIEW 36 5.3.2 IMPACT ON SUPPLY CHAIN 37 5.3.3 IMPACT ON PRODUCTION 37 5.3.4 IMPACT ON KEY PLAYERS 37 5.3.5 IMPACT ON REGIONS 37 6 GLOBAL COMPANION DIAGNOSTICS FOR ONCOLOGY MARKET, BY PRODUCTS & SERVICES 6.1 OVERVIEW 38 6.2 ASSAYS, KITS & REAGENTS 39 6.3 SOFTWARE & SERVICES 40 7 GLOBAL COMPANION DIAGNOSTICS FOR ONCOLOGY MARKET, BY TECHNOLOGY 7.1 OVERVIEW 41 7.2 POLYMERASE CHAIN REACTION (PCR) 42 7.3 NEXT-GENERATION SEQUENCING (NGS) 43 8 GLOBAL COMPANION DIAGNOSTICS FOR ONCOLOGY MARKET, BY INDICATION 8.1 OVERVIEW 44 8.2 LUNG CANCER 46 8.3 BREAST CANCER 46 8.4 COLORECTAL CANCER 47 8.5 GASTRIC CANCER 47 8.6 MELANOMA 48 9 GLOBAL COMPANION DIAGNOSTICS FOR ONCOLOGY MARKET, BY END USER 9.1 OVERVIEW 49 9.2 PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES 51 9.3 CONTRACT RESEARCH ORGANIZATIONS 51 9.4 LABORATORIES 52 10 GLOBAL COMPANION DIAGNOSTICS FOR ONCOLOGY MARKET, BY REGION 10.1 OVERVIEW 53 10.2 AMERICAS 55 10.2.1 NORTH AMERICA 57 10.2.1.1 US 59 10.2.1.2 CANADA 60 10.2.2 LATIN AMERICA 62 10.3 EUROPE 64 10.3.1 WESTERN EUROPE 66 10.3.1.1 GERMANY 68 10.3.1.2 UK 70 10.3.1.3 FRANCE 71 10.3.1.4 ITALY 72 10.3.1.5 SPAIN 74 10.3.1.6 REST OF WESTERN EUROPE 75 10.3.2 EASTERN EUROPE 77 10.4 ASIA-PACIFIC 79 10.4.1 CHINA 81 10.4.2 JAPAN 82 10.4.3 INDIA 84 10.4.4 AUSTRALIA 85 10.4.5 SOUTH KOREA 87 10.4.6 REST OF ASIA-PACIFIC 88 10.5 MIDDLE EAST & AFRICA 90 10.5.1 MIDDLE EAST 92 10.5.2 AFRICA 93 11 COMPETITIVE LANDSCAPE 11.1 OVERVIEW 95 11.2 COMPETITIVE BENCHMARKING 96 11.3 GLOBAL COMPANION DIAGNOSTICS FOR ONCOLOGY MARKET: COMPANY RANKING 97 11.4 MAJOR GROWTH STRATEGY IN THE GLOBAL COMPANION DIAGNOSTICS FOR ONCOLOGY MARKET 98 11.5 LEADING PLAYERS IN TERMS OF NUMBER OF DEVELOPMENTS 98 11.6 KEY DEVELOPMENTS & GROWTH STRATEGIES 99 11.6.1 PRODUCT APPROVALS AND LAUNCHES 99 11.6.2 JOINT VENTURES 102 11.6.3 EXPANSIONS 105 11.6.4 ACQUISITIONS 105 11.7 FINANCIAL MATRIX 106 12 COMPANY PROFILES 12.1 F. HOFFMANN-LA ROCHE LTD 107 12.1.1 COMPANY OVERVIEW 107 12.1.2 FINANCIAL OVERVIEW 108 12.1.3 PRODUCTS/SERVICES OFFERED 108 12.1.4 KEY DEVELOPMENTS 109 12.1.5 SWOT ANALYSIS 110 12.1.6 KEY STRATEGIES 110 12.2 THERMO FISHER SCIENTIFIC INC. 111 12.2.1 COMPANY OVERVIEW 111 12.2.2 FINANCIAL OVERVIEW 111 12.2.3 PRODUCTS/SERVICES OFFERED 112 12.2.4 KEY DEVELOPMENTS 112 12.2.5 SWOT ANALYSIS 113 12.2.6 KEY STRATEGIES 113 12.3 QIAGEN 114 12.3.1 COMPANY OVERVIEW 114 12.3.2 FINANCIAL OVERVIEW 114 12.3.3 PRODUCTS/SERVICES OFFERED 115 12.3.4 KEY DEVELOPMENTS 115 12.3.5 SWOT ANALYSIS 117 12.3.6 KEY STRATEGIES 117 12.4 BIOMÉRIEUX SA 118 12.4.1 COMPANY OVERVIEW 118 12.4.2 FINANCIAL OVERVIEW 118 12.4.3 PRODUCTS/SERVICES OFFERED 119 12.4.4 KEY DEVELOPMENTS 119 12.4.5 SWOT ANALYSIS 119 12.4.6 KEY STRATEGIES 119 12.5 ILLUMINA, INC. 120 12.5.1 COMPANY OVERVIEW 120 12.5.2 FINANCIAL OVERVIEW 120 12.5.3 PRODUCTS/SERVICES OFFERED 121 12.5.4 KEY DEVELOPMENTS 121 12.5.5 SWOT ANALYSIS 122 12.5.6 KEY STRATEGIES 122 12.6 ARCHERDX, INC. 123 12.6.1 COMPANY OVERVIEW 123 12.6.2 FINANCIAL OVERVIEW 123 12.6.3 PRODUCTS/SERVICES OFFERED 123 12.6.4 KEY DEVELOPMENTS 124 12.6.5 SWOT ANALYSIS 125 12.6.6 KEY STRATEGIES 125 12.7 FOUNDATION MEDICINE, INC. 126 12.7.1 COMPANY OVERVIEW 126 12.7.2 FINANCIAL OVERVIEW 126 12.7.3 PRODUCTS/SERVICES OFFERED 126 12.7.4 KEY DEVELOPMENTS 127 12.7.5 SWOT ANALYSIS 128 12.7.6 KEY STRATEGIES 128 12.8 AMOY DIAGNOSTICS CO. LTD 129 12.8.1 COMPANY OVERVIEW 129 12.8.2 FINANCIAL OVERVIEW 129 12.8.3 PRODUCTS/SERVICES OFFERED 129 12.8.4 KEY DEVELOPMENTS 130 12.8.5 SWOT ANALYSIS 131 12.8.6 KEY STRATEGIES 131 12.9 AGILENT TECHNOLOGIES, INC. 132 12.9.1 COMPANY OVERVIEW 132 12.9.2 FINANCIAL OVERVIEW 132 12.9.3 PRODUCTS/SERVICES OFFERED 133 12.9.4 KEY DEVELOPMENTS 133 12.9.5 SWOT ANALYSIS 134 12.9.6 KEY STRATEGIES 134 12.10 ABBOTT 135 12.10.1 COMPANY OVERVIEW 135 12.10.2 FINANCIAL OVERVIEW 135 12.10.3 PRODUCTS/SERVICES OFFERED 136 12.10.4 KEY DEVELOPMENTS 136 12.10.5 SWOT ANALYSIS 136 12.10.6 KEY STRATEGIES 137 13 APPENDIX 13.1 REFERENCES 138 13.2 RELATED REPORTS 138

LIST OF TABLES TABLE 1 LIST OF ASSUMPTIONS & LIMITATIONS 19 TABLE 2 PRIMARY INTERVIEWS AND INFORMATION GATHERING PROCESS 22 TABLE 3 GLOBAL COMPANION DIAGNOSTICS FOR ONCOLOGY MARKET, BY PRODUCTS & SERVICES, 2020-2027 (USD MILLION) 39 TABLE 4 GLOBAL COMPANION DIAGNOSTICS FOR ONCOLOGY MARKET, FOR ASSAYS, KITS & REAGENTS, BY REGION, 2020-2027 (USD MILLION) 39 TABLE 5 GLOBAL COMPANION DIAGNOSTICS FOR ONCOLOGY MARKET, FOR SOFTWARE & SERVICES, BY REGION, 2020-2027 (USD MILLION) 40 TABLE 6 GLOBAL COMPANION DIAGNOSTICS FOR ONCOLOGY MARKET, BY TECHNOLOGY, 2020-2027 (USD MILLION) 42 TABLE 7 GLOBAL COMPANION DIAGNOSTICS FOR ONCOLOGY MARKET, FOR PCR, BY REGION, 2020-2027 (USD MILLION) 42 TABLE 8 GLOBAL COMPANION DIAGNOSTICS FOR ONCOLOGY MARKET, FOR NGS, BY REGION, 2020-2027 (USD MILLION) 43 TABLE 9 GLOBAL COMPANION DIAGNOSTICS FOR ONCOLOGY MARKET, BY INDICATION, 2020-2027 (USD MILLION) 45 TABLE 10 GLOBAL COMPANION DIAGNOSTICS FOR ONCOLOGY MARKET, FOR LUNG CANCER, BY REGION, 2020-2027 (USD MILLION) 46 TABLE 11 GLOBAL COMPANION DIAGNOSTICS FOR ONCOLOGY MARKET, FOR BREAST CANCER, BY REGION, 2020-2027 (USD MILLION) 46 TABLE 12 GLOBAL COMPANION DIAGNOSTICS FOR ONCOLOGY MARKET, FOR COLORECTAL CANCER, BY REGION, 2020-2027 (USD MILLION) 47 TABLE 13 GLOBAL COMPANION DIAGNOSTICS FOR ONCOLOGY MARKET, FOR GASTRIC CANCER, BY REGION, 2020-2027 (USD MILLION) 47 TABLE 14 GLOBAL COMPANION DIAGNOSTICS FOR ONCOLOGY MARKET, FOR MELANOMA, BY REGION, 2020-2027 (USD MILLION) 48 TABLE 15 GLOBAL COMPANION DIAGNOSTICS FOR ONCOLOGY MARKET, BY END USER, 2020-2027 (USD MILLION) 50 TABLE 16 GLOBAL COMPANION DIAGNOSTICS FOR ONCOLOGY MARKET, FOR PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES, BY REGION, 2020-2027 (USD MILLION) 51 TABLE 17 GLOBAL COMPANION DIAGNOSTICS FOR ONCOLOGY MARKET, FOR CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2020-2027 (USD MILLION) 52 TABLE 18 GLOBAL COMPANION DIAGNOSTICS FOR ONCOLOGY MARKET, FOR LABORATORIES, BY REGION, 2020-2027 (USD MILLION) 52 TABLE 19 GLOBAL: COMPANION DIAGNOSTICS FOR ONCOLOGY MARKET, BY REGION, 2020–2027 (USD MILLION) 54 TABLE 20 AMERICAS: COMPANION DIAGNOSTICS FOR ONCOLOGY MARKET, BY REGION, 2020–2027 (USD MILLION) 55 TABLE 21 AMERICAS: COMPANION DIAGNOSTICS FOR ONCOLOGY MARKET, BY PRODUCTS & SERVICES, 2020–2027 (USD MILLION) 56 TABLE 22 AMERICAS: COMPANION DIAGNOSTICS FOR ONCOLOGY MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION) 56 TABLE 23 AMERICAS: COMPANION DIAGNOSTICS FOR ONCOLOGY MARKET, BY INDICATION, 2020–2027 (USD MILLION) 56 TABLE 24 AMERICAS: COMPANION DIAGNOSTICS FOR ONCOLOGY MARKET, BY END USER, 2020–2027 (USD MILLION) 57 TABLE 25 NORTH AMERICA: COMPANION DIAGNOSTICS FOR ONCOLOGY MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 57 TABLE 26 NORTH AMERICA: COMPANION DIAGNOSTICS FOR ONCOLOGY MARKET, BY PRODUCTS & SERVICES, 2020–2027 (USD MILLION) 58 TABLE 27 NORTH AMERICA: COMPANION DIAGNOSTICS FOR ONCOLOGY MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION) 58 TABLE 28 NORTH AMERICA: COMPANION DIAGNOSTICS FOR ONCOLOGY MARKET, BY INDICATION, 2020–2027 (USD MILLION) 58 TABLE 29 NORTH AMERICA: COMPANION DIAGNOSTICS FOR ONCOLOGY MARKET, BY END USER, 2020–2027 (USD MILLION) 59 TABLE 30 US: COMPANION DIAGNOSTICS FOR ONCOLOGY MARKET, BY PRODUCTS & SERVICES, 2020–2027 (USD MILLION) 59 TABLE 31 US: COMPANION DIAGNOSTICS FOR ONCOLOGY MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION) 59 TABLE 32 US: COMPANION DIAGNOSTICS FOR ONCOLOGY MARKET, BY INDICATION, 2020–2027 (USD MILLION) 60 TABLE 33 US: COMPANION DIAGNOSTICS FOR ONCOLOGY MARKET, BY END USER, 2020–2027 (USD MILLION) 60 TABLE 34 CANADA: COMPANION DIAGNOSTICS FOR ONCOLOGY MARKET, BY PRODUCTS & SERVICES, 2020–2027 (USD MILLION) 60 TABLE 35 CANADA: COMPANION DIAGNOSTICS FOR ONCOLOGY MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION) 61 TABLE 36 CANADA: COMPANION DIAGNOSTICS FOR ONCOLOGY MARKET, BY INDICATION, 2020–2027 (USD MILLION) 61 TABLE 37 CANADA: COMPANION DIAGNOSTICS FOR ONCOLOGY MARKET, BY END USER, 2020–2027 (USD MILLION) 61 TABLE 38 LATIN AMERICA: COMPANION DIAGNOSTICS FOR ONCOLOGY MARKET, BY PRODUCTS & SERVICES, 2020–2027 (USD MILLION) 62 TABLE 39 LATIN AMERICA: COMPANION DIAGNOSTICS FOR ONCOLOGY MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION) 62 TABLE 40 LATIN AMERICA: COMPANION DIAGNOSTICS FOR ONCOLOGY MARKET, BY INDICATION, 2020–2027 (USD MILLION) 62 TABLE 41 LATIN AMERICA: COMPANION DIAGNOSTICS FOR ONCOLOGY MARKET, BY END USER, 2020–2027 (USD MILLION) 63 TABLE 42 EUROPE: COMPANION DIAGNOSTICS FOR ONCOLOGY MARKET, BY REGION, 2020-2027 (USD MILLION) 64 TABLE 43 EUROPE: COMPANION DIAGNOSTICS FOR ONCOLOGY MARKET, BY PRODUCTS & SERVICES, 2020–2027 (USD MILLION) 65 TABLE 44 EUROPE: COMPANION DIAGNOSTICS FOR ONCOLOGY MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION) 65 TABLE 45 EUROPE: COMPANION DIAGNOSTICS FOR ONCOLOGY MARKET, BY INDICATION, 2020–2027 (USD MILLION) 65 TABLE 46 EUROPE: COMPANION DIAGNOSTICS FOR ONCOLOGY MARKET, BY END USER, 2020–2027 (USD MILLION) 66 TABLE 47 WESTERN EUROPE: COMPANION DIAGNOSTICS FOR ONCOLOGY MARKET, BY COUNTRY, 2020-2027 (USD MILLION) 67 TABLE 48 WESTERN EUROPE: COMPANION DIAGNOSTICS FOR ONCOLOGY MARKET, BY PRODUCTS & SERVICES, 2020–2027 (USD MILLION) 67 TABLE 49 WESTERN EUROPE: COMPANION DIAGNOSTICS FOR ONCOLOGY MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION) 67 TABLE 50 WESTERN EUROPE: COMPANION DIAGNOSTICS FOR ONCOLOGY MARKET, BY INDICATION, 2020–2027 (USD MILLION) 68 TABLE 51 WESTERN EUROPE: COMPANION DIAGNOSTICS FOR ONCOLOGY MARKET, BY END USER, 2020–2027 (USD MILLION) 68 TABLE 52 GERMANY: COMPANION DIAGNOSTICS FOR ONCOLOGY MARKET, BY PRODUCTS & SERVICES, 2020–2027 (USD MILLION) 68 TABLE 53 GERMANY: COMPANION DIAGNOSTICS FOR ONCOLOGY MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION) 69 TABLE 54 GERMANY: COMPANION DIAGNOSTICS FOR ONCOLOGY MARKET, BY INDICATION, 2020–2027 (USD MILLION) 69 TABLE 55 GERMANY: COMPANION DIAGNOSTICS FOR ONCOLOGY MARKET, BY END USER, 2020–2027 (USD MILLION) 69 TABLE 56 UK: COMPANION DIAGNOSTICS FOR ONCOLOGY MARKET, BY PRODUCTS & SERVICES, 2020–2027 (USD MILLION) 70 TABLE 57 UK: COMPANION DIAGNOSTICS FOR ONCOLOGY MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION) 70 TABLE 58 UK: COMPANION DIAGNOSTICS FOR ONCOLOGY MARKET, BY INDICATION, 2020–2027 (USD MILLION) 70 TABLE 59 UK: COMPANION DIAGNOSTICS FOR ONCOLOGY MARKET, BY END USER, 2020–2027 (USD MILLION) 71 TABLE 60 FRANCE: COMPANION DIAGNOSTICS FOR ONCOLOGY MARKET, BY PRODUCTS & SERVICES, 2020–2027 (USD MILLION) 71 TABLE 61 FRANCE: COMPANION DIAGNOSTICS FOR ONCOLOGY MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION) 71 TABLE 62 FRANCE: COMPANION DIAGNOSTICS FOR ONCOLOGY MARKET, BY INDICATION, 2020–2027 (USD MILLION) 72 TABLE 63 FRANCE: COMPANION DIAGNOSTICS FOR ONCOLOGY MARKET, BY END USER, 2020–2027 (USD MILLION) 72 TABLE 64 ITALY: COMPANION DIAGNOSTICS FOR ONCOLOGY MARKET, BY PRODUCTS & SERVICES, 2020–2027 (USD MILLION) 72 TABLE 65 ITALY: COMPANION DIAGNOSTICS FOR ONCOLOGY MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION) 73 TABLE 66 ITALY: COMPANION DIAGNOSTICS FOR ONCOLOGY MARKET, BY INDICATION, 2020–2027 (USD MILLION) 73 TABLE 67 ITALY: COMPANION DIAGNOSTICS FOR ONCOLOGY MARKET, BY END USER, 2020–2027 (USD MILLION) 73 TABLE 68 SPAIN: COMPANION DIAGNOSTICS FOR ONCOLOGY MARKET, BY PRODUCTS & SERVICES, 2020–2027 (USD MILLION) 74 TABLE 69 SPAIN: COMPANION DIAGNOSTICS FOR ONCOLOGY MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION) 74 TABLE 70 SPAIN: COMPANION DIAGNOSTICS FOR ONCOLOGY MARKET, BY INDICATION, 2020–2027 (USD MILLION) 74 TABLE 71 SPAIN: COMPANION DIAGNOSTICS FOR ONCOLOGY MARKET, BY END USER, 2020–2027 (USD MILLION) 75 TABLE 72 REST OF WESTERN EUROPE: COMPANION DIAGNOSTICS FOR ONCOLOGY MARKET, BY PRODUCTS & SERVICES, 2020–2027 (USD MILLION) 75 TABLE 73 REST OF WESTERN EUROPE: COMPANION DIAGNOSTICS FOR ONCOLOGY MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION) 75 TABLE 74 REST OF WESTERN EUROPE: COMPANION DIAGNOSTICS FOR ONCOLOGY MARKET, BY INDICATION, 2020–2027 (USD MILLION) 76 TABLE 75 REST OF WESTERN EUROPE: COMPANION DIAGNOSTICS FOR ONCOLOGY MARKET, BY END USER, 2020–2027 (USD MILLION) 76 TABLE 76 EASTERN EUROPE: COMPANION DIAGNOSTICS FOR ONCOLOGY MARKET, BY PRODUCTS & SERVICES, 2020–2027 (USD MILLION) 77 TABLE 77 EASTERN EUROPE: COMPANION DIAGNOSTICS FOR ONCOLOGY MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION) 77 TABLE 78 EASTERN EUROPE: COMPANION DIAGNOSTICS FOR ONCOLOGY MARKET, BY INDICATION, 2020–2027 (USD MILLION) 77 TABLE 79 EASTERN EUROPE: COMPANION DIAGNOSTICS FOR ONCOLOGY MARKET, BY END USER, 2020–2027 (USD MILLION) 78 TABLE 80 ASIA-PACIFIC: COMPANION DIAGNOSTICS FOR ONCOLOGY MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 79 TABLE 81 ASIA-PACIFIC: COMPANION DIAGNOSTICS FOR ONCOLOGY MARKET, BY PRODUCTS & SERVICES, 2020–2027 (USD MILLION) 80 TABLE 82 ASIA-PACIFIC: COMPANION DIAGNOSTICS FOR ONCOLOGY MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION) 80 TABLE 83 ASIA-PACIFIC: COMPANION DIAGNOSTICS FOR ONCOLOGY MARKET, BY INDICATION, 2020–2027 (USD MILLION) 80 TABLE 84 ASIA-PACIFIC: COMPANION DIAGNOSTICS FOR ONCOLOGY MARKET, BY END USER, 2020–2027 (USD MILLION) 81 TABLE 85 CHINA: COMPANION DIAGNOSTICS FOR ONCOLOGY MARKET, BY PRODUCTS & SERVICES, 2020–2027 (USD MILLION) 81 TABLE 86 CHINA: COMPANION DIAGNOSTICS FOR ONCOLOGY MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION) 81 TABLE 87 CHINA: COMPANION DIAGNOSTICS FOR ONCOLOGY MARKET, BY INDICATION, 2020–2027 (USD MILLION) 82 TABLE 88 CHINA: COMPANION DIAGNOSTICS FOR ONCOLOGY MARKET, BY END USER, 2020–2027 (USD MILLION) 82 TABLE 89 JAPAN: COMPANION DIAGNOSTICS FOR ONCOLOGY MARKET, BY PRODUCTS & SERVICES, 2020–2027 (USD MILLION) 82 TABLE 90 JAPAN: COMPANION DIAGNOSTICS FOR ONCOLOGY MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION) 83 TABLE 91 JAPAN: COMPANION DIAGNOSTICS FOR ONCOLOGY MARKET, BY INDICATION, 2020–2027 (USD MILLION) 83 TABLE 92 JAPAN: COMPANION DIAGNOSTICS FOR ONCOLOGY MARKET, BY END USER, 2020–2027 (USD MILLION) 83 TABLE 93 INDIA: COMPANION DIAGNOSTICS FOR ONCOLOGY MARKET, BY PRODUCTS & SERVICES, 2020–2027 (USD MILLION) 84 TABLE 94 INDIA: COMPANION DIAGNOSTICS FOR ONCOLOGY MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION) 84 TABLE 95 INDIA: COMPANION DIAGNOSTICS FOR ONCOLOGY MARKET, BY INDICATION, 2020–2027 (USD MILLION) 84 TABLE 96 INDIA: COMPANION DIAGNOSTICS FOR ONCOLOGY MARKET, BY END USER, 2020–2027 (USD MILLION) 85 TABLE 97 AUSTRALIA: COMPANION DIAGNOSTICS FOR ONCOLOGY MARKET, BY PRODUCTS & SERVICES, 2020–2027 (USD MILLION) 85 TABLE 98 AUSTRALIA: COMPANION DIAGNOSTICS FOR ONCOLOGY MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION) 85 TABLE 99 AUSTRALIA: COMPANION DIAGNOSTICS FOR ONCOLOGY MARKET, BY INDICATION, 2020–2027 (USD MILLION) 86 TABLE 100 AUSTRALIA: COMPANION DIAGNOSTICS FOR ONCOLOGY MARKET, BY END USER, 2020–2027 (USD MILLION) 86 TABLE 101 SOUTH KOREA: COMPANION DIAGNOSTICS FOR ONCOLOGY MARKET, BY PRODUCTS & SERVICES, 2020–2027 (USD MILLION) 87 TABLE 102 SOUTH KOREA: COMPANION DIAGNOSTICS FOR ONCOLOGY MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION) 87 TABLE 103 SOUTH KOREA: COMPANION DIAGNOSTICS FOR ONCOLOGY MARKET, BY INDICATION, 2020–2027 (USD MILLION) 87 TABLE 104 SOUTH KOREA: COMPANION DIAGNOSTICS FOR ONCOLOGY MARKET, BY END USER, 2020–2027 (USD MILLION) 88 TABLE 105 REST OF ASIA-PACIFIC: COMPANION DIAGNOSTICS FOR ONCOLOGY MARKET, BY PRODUCTS & SERVICES, 2020–2027 (USD MILLION) 88 TABLE 106 REST OF ASIA-PACIFIC: COMPANION DIAGNOSTICS FOR ONCOLOGY MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION) 88 TABLE 107 REST OF ASIA-PACIFIC: COMPANION DIAGNOSTICS FOR ONCOLOGY MARKET, BY INDICATION, 2020–2027 (USD MILLION) 89 TABLE 108 REST OF ASIA-PACIFIC: COMPANION DIAGNOSTICS FOR ONCOLOGY MARKET, BY END USER, 2020–2027 (USD MILLION) 89 TABLE 109 MIDDLE EAST & AFRICA: COMPANION DIAGNOSTICS FOR ONCOLOGY MARKET, BY REGION, 2020–2027 (USD MILLION) 90 TABLE 110 MIDDLE EAST & AFRICA: COMPANION DIAGNOSTICS FOR ONCOLOGY MARKET, BY PRODUCTS & SERVICES, 2020–2027 (USD MILLION) 90 TABLE 111 MIDDLE EAST & AFRICA: COMPANION DIAGNOSTICS FOR ONCOLOGY MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION) 91 TABLE 112 MIDDLE EAST & AFRICA: COMPANION DIAGNOSTICS FOR ONCOLOGY MARKET, BY INDICATION, 2020–2027 (USD MILLION) 91 TABLE 113 MIDDLE EAST & AFRICA: COMPANION DIAGNOSTICS FOR ONCOLOGY MARKET, BY END USER, 2020–2027 (USD MILLION) 91 TABLE 114 MIDDLE EAST: COMPANION DIAGNOSTICS FOR ONCOLOGY MARKET, BY PRODUCTS & SERVICES, 2020–2027 (USD MILLION) 92 TABLE 115 MIDDLE EAST: COMPANION DIAGNOSTICS FOR ONCOLOGY MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION) 92 TABLE 116 MIDDLE EAST: COMPANION DIAGNOSTICS FOR ONCOLOGY MARKET, BY INDICATION, 2020–2027 (USD MILLION) 92 TABLE 117 MIDDLE EAST: COMPANION DIAGNOSTICS FOR ONCOLOGY MARKET, BY END USER, 2020–2027 (USD MILLION) 93 TABLE 118 AFRICA: COMPANION DIAGNOSTICS FOR ONCOLOGY MARKET, BY PRODUCTS & SERVICES, 2020–2027 (USD MILLION) 93 TABLE 119 AFRICA: COMPANION DIAGNOSTICS FOR ONCOLOGY MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION) 93 TABLE 120 AFRICA: COMPANION DIAGNOSTICS FOR ONCOLOGY MARKET, BY INDICATION, 2020–2027 (USD MILLION) 94 TABLE 121 AFRICA: COMPANION DIAGNOSTICS FOR ONCOLOGY MARKET, BY END USER, 2020–2027 (USD MILLION) 94 TABLE 122 TOP PLAYERS IN TERMS OF NUMBER OF DEVELOPMENTS IN THE GLOBAL COMPANION DIAGNOSTICS FOR ONCOLOGY MARKET 98 TABLE 123 PRODUCT APPROVALS AND LAUNCHES 99 TABLE 124 JOINT VENTURES 102 TABLE 125 EXPANSIONS 105 TABLE 126 ACQUISITIONS 105 TABLE 127 F. HOFFMANN-LA ROCHE LTD: PRODUCTS/SERVICES OFFERED 108 TABLE 128 F. HOFFMANN-LA ROCHE LTD: KEY DEVELOPMENTS 109 TABLE 129 THERMO FISHER SCIENTIFIC INC.: PRODUCTS/SERVICES OFFERED 112 TABLE 130 THERMO FISHER SCIENTIFIC INC.: KEY DEVELOPMENTS 112 TABLE 131 QIAGEN: PRODUCTS/SERVICES OFFERED 115 TABLE 132 QIAGEN: KEY DEVELOPMENTS 115 TABLE 133 BIOMÉRIEUX SA: PRODUCTS/SERVICES OFFERED 119 TABLE 134 ILLUMINA, INC.: PRODUCTS/SERVICES OFFERED 121 TABLE 135 ILLUMINA, INC.: KEY DEVELOPMENTS 121 TABLE 136 ARCHERDX, INC.: PRODUCTS/SERVICES OFFERED 123 TABLE 137 ARCHERDX, INC.: KEY DEVELOPMENTS 124 TABLE 138 FOUNDATION MEDICINE, INC.: PRODUCTS/SERVICES OFFERED 126 TABLE 139 FOUNDATION MEDICINE, INC.: KEY DEVELOPMENTS 127 TABLE 140 AMOY DIAGNOSTICS CO LTD.: PRODUCTS/SERVICES OFFERED 129 TABLE 141 AMOY DIAGNOSTICS CO.LTD.: KEY DEVELOPMENTS 130 TABLE 142 AGILENT TECHNOLOGIES, INC.: PRODUCTS/SERVICES OFFERED 133 TABLE 143 AGILENT TECHNOLOGIES, INC.: KEY DEVELOPMENTS 133 TABLE 144 ABBOTT: PRODUCTS/SERVICES OFFERED 136 TABLE 145 ABBOTT: KEY DEVELOPMENTS 136